Three significant cases of neutropenia with etanercept [3]

Rheumatology

Volumn 47, Issue 3, 2008, Pages 376-377

  Wenham, C ^a   Gadsby, K ^a   Deighton, Chris ^a  

^a DERBYSHIRE ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GENTAMICIN; METHOTREXATE; PIPERACILLIN PLUS TAZOBACTAM; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; ANAMNESIS; BLOOD CULTURE; BONE MARROW EXAMINATION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECHOGRAPHY; FEMALE; GINGIVA HYPERTROPHY; HEMATOPOIESIS; HUMAN; HYPERTENSION; INTENSIVE CARE UNIT; LAPAROTOMY; LETTER; LEUKOCYTE COUNT; LEUKOPENIA; MAINTENANCE THERAPY; MALE; NEUTROPENIA; NEUTROPHIL COUNT; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RETREATMENT; RHEUMATOID ARTHRITIS; SPLENECTOMY; STAPHYLOCOCCUS INFECTION;

ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NEUTROPENIA; RECEPTORS, TUMOR NECROSIS FACTOR; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 39449135911     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem332     Document Type: Letter

References (9)

1. Ledingham J, Deighton C. Update on the British Society of Rheumatology guidelines for prescribing TNF alpha blockers in adults with rheumatoid arthritis. Rheumatology 2005;44:157-63.
2. Furst D, Schiff M, Fleishmann R et al. Results of safety trial of adalimumab in rheumatoid arthritis. J Rheumatol 2003;30:2563-72.
3. Fleishmann R, Iqbal I, Nandeshwar P, Quiceno A. Safety and efficacy of disease-modifying anti-rheumatic agents: Focus on the benefit and risk of etanercept. Drug Safety 2002;25:173-97.
4. Ang H, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumour necrosis factor-alpha antagonists In patients with rheumatoid arthritis? J Rheumatol 2003;30:2315-8.
5. Rajakulendran S, Gadsby K, Allen D et al. Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis. Ann Rheum Dis. 2006;65:1678-9.
6. Montane E, Salles M, Bamocanal A et al. Anti-tumor necrosis factor-induced neutropaenia a case report with double positive rechallenges. Clin Rheumatol 2007;26:1527-9.
7. Vidal F, Fontova R, Richart C. Severe neutropeania and thrombocytopeania associated with infilximab. Ann Intern Med 2003;139:63.
8. Favalli EG, Varenna M, Sinoglia L. Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy. Clin Exp Rheumatol 2005;2:247-50.
9. Yazdani R, Simpson H, Kaushik W. Incidence of cytopaenias with anti-TNF therapy. Rheumatology 2007;46(Suppl. 1):133.